Late cerebral relapse of a Mycobacterium avium complex disseminated infection in an HIV-infected patient after cessation of antiretroviral therapy [3]

AIDS

Volumn 17, Issue 9, 2003, Pages 1410-1411

  Lascaux, Anne Sophie ^a   Lesprit, Philippe ^a   Deforges, Lionel ^a   Gutierrez, Cristina ^b   Lévy, Yves ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b CENTRE NATIONAL DE RECHERCHES MÉTÉOROLOGIQUES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; BACTERIAL DNA; CD4 ANTIGEN; CLARITHROMYCIN; ETHAMBUTOL; INDINAVIR; LAMIVUDINE; PYRIMETHAMINE SULFADIAZINE; RIFABUTIN; STAVUDINE; TUBERCULOSTATIC AGENT; VIRUS RNA;

ADULT; BLOOD CULTURE; BRAIN INFECTION; CASE REPORT; CENTRAL NERVOUS SYSTEM INFECTION; COMPUTER ASSISTED TOMOGRAPHY; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LEUKOCYTE COUNT; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; NONHUMAN; OPPORTUNISTIC INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIDE EFFECT; TOXOPLASMA GONDII; TOXOPLASMOSIS; VIRUS INFECTION; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; HIV INFECTIONS; HUMANS; MALE; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; RECURRENCE; TIME FACTORS; TUBERCULOSIS, CENTRAL NERVOUS SYSTEM;

EID: 0038336926     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200306130-00024     Document Type: Letter

References (9)

1. Picardeau M, Vincent V. Typing of Mycobacterium avium isolates by PCR. J Clin Microbiol 1996, 34:389-392.
2. Murray R, Mallal S, Heath C, French M. Cerebral Mycobacterium avium infection in an HIV-infected patient following immune reconstitution and cessation of therapy for disseminated Mycobacterium avium complex infection. Eur J Clin Microbiol Infect Dis 2001, 20:199-201.
3. Lopez Bernaldo de Quiros JC, Miro JM, Pena JM, Podzamczer D, Alberdi JC, Martinez E, et al. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis cariini pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de estudio del SIDA 04/98. N Engl J Med 2001, 344: 159-167.
4. Guex AC, Radziwill AJ, Bucher HC. Discontinuation of secondary prophylaxis for toxoplasmic encephalitis in human immunodeficiency virus infection after immune restoration with highly active antiretroviral therapy. Clin Infect Dis 2000, 30:602-603.
5. Aberg JA, Yajko DM, Jacobson MA. Eradication of AIDS-related disseminated Mycobacterium avium complex infection after 12 months of antimycobacterial therapy combined with highly active antiretroviral therapy. J Infect Dis 1998, 178:1446-1449.
6. Martinez E, Miro JM, Gonzalez J, Mallolas J, Gatell JM. Withdrawal of mycobacterium avium complex suppressive therapy in HIV-1-infected patients on highly active antiretroviral therapy. AIDS 1999, 13:147-148.
7. Soriano V, Dona C, Rodriguez-Rosado R, Barreiro P, Gonzalez-Lahoz J. Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 2000, 14:383-386.
8. Kirk O, Reiss P, Uberti-Foppa C, Bickel M, Gerstoft J, Pradier C, et al. Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med 2002, 137:239-250.
9. Shafran SD, Mashinter LD, Phillips P, Lalonde RG, Gill MJ, Walmsley SL, et al. Successful discontinuation of therapy for disseminated Mycobacterium avium complex infection after effective antiretroviral therapy. Ann Intern Med 2002, 137: 734-737.